RxDoctor Payments Data

Ricardo Saiz

Medical · Pembroke Pines, FLNPI 1821220963

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 1,035 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 12.9% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$22,099in general payments, 2019–2025

Across 1,035 payments — averaging $21.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$3K
  • AstraZeneca$3K
  • Actelion Pharmaceuticals US, Inc.$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • Boehringer Ingelheim$2K
  • United Therapeutics Corporation$1K
  • plus $10K from 36 others

What the payments were for

  • Food & beverage$21,82299%
  • Education$2771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,099 in reported general payments places this provider in the 95th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab127$502,999
OfevNintedanib Esylate28$362,564
Trelegy ElliptaFluticasone/Umeclidin/Vilanter388$320,852
OpsumitMacitentan14$176,591
Breztri AerosphereBudesonide/Glycopyr/Formoterol200$141,062
NucalaMepolizumab26$95,078
Dupixent SyringeDupilumab24$94,677
Stiolto RespimatTiotropium Br/Olodaterol Hcl67$39,732
Breo ElliptaFluticasone/Vilanterol66$35,103
Spiriva RespimatTiotropium Bromide39$22,012
SymbicortBudesonide/Formoterol Fumarate68$19,476
EliquisApixaban17$12,689
Atrovent HfaIpratropium Bromide27$12,587
XareltoRivaroxaban17$8,976
Albuterol Sulfate HfaAlbuterol Sulfate255$6,930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$2,843$461,620508 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,504$424,309134 claims
Actelion Pharmaceuticals US, Inc.Opsumit$2,070$176,59114 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,786$160,538268 claims
PfizerEliquis$50$12,68917 claims
Johnson & JohnsonXarelto$54$8,97617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,031 medical providers in Florida.

Other medical in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →